Karyopharm Therapeutics(US:KPTI)2026-02-18 15:02Summary of Karyopharm Therapeutics Special Meeting Company Overview - Company: Karyopharm Therapeutics, Inc. (NasdaqGS: KPTI) - Meeting Date: February 18, 2026 - Participants: Richard Paulson (President, CEO, and Director), Michael Mano (Chief Legal Officer), Lori Macomber (Chief Financial Officer), Brendan Strong (Senior Vice President of Investor Relations) [1][2][3] Key Proposals Discussed 1. Proposal One: - Adoption and approval of an amendment to the restated certificate of incorporation to increase the number of authorized shares of capital stock from 58,333,333 to 111,000,000. - Increase the number of authorized shares of common stock from 53,333,333 to 106,000,000 [7][9]. 2. Proposal Two: - Approval to adjourn the special meeting to a later date if necessary for further solicitation of proxies in case of insufficient votes for Proposal One [7][10]. Voting Results - A quorum was established with 18,310,283 shares of common stock entitled to vote present [5][6]. - Both proposals were approved based on preliminary voting results: - Proposal One to increase authorized shares was approved. - Proposal Two to allow for adjournment was also approved [9][10]. Important Notes - The meeting was conducted in a virtual format, allowing stockholders to participate similarly to an in-person meeting [2]. - Forward-looking statements were made, with a disclaimer regarding reliance on these statements due to potential differences in actual results [4]. - The final vote results will be documented in a Form 8-K to be filed within four business days after the meeting [10]. Additional Information - Stockholders were encouraged to submit questions related solely to the proposals during the meeting, but no questions were raised [7][8]. - The meeting concluded with gratitude expressed to shareholders for their participation and support [10].